Novasep has expanded its highly potent active pharmaceutical ingredients (HPAPIs) manufacturing capabilities on its Le Mans, France site.
 
To support this growth and sustain the increase in both clinical and commercial production capacity, Novasep is recruiting more than 30 people at this site, combined with an investment of more than €4 million.
 
Novasep has been a key partner to innovators in the ADC arena for more than 15 years. With a strong pipeline of customer’s clinical drug candidates leading to a number of recent ADC drug approvals, Novasep’s strategy of offering integrated development and manufacturing services for both payloads and bioconjugation is now bearing fruit.
 
The state-of-the-art bioconjugation facility, launched in 2017 with an investment of €12 million, delivers cGMP ADC batches to customers and was successfully inspected by the ANSM (French regulatory drug authorities) in 2021.
 
“We are pleased to continue our development in strategic markets such as HPAPIs and ADCs, and to participate in the fight against cancer for the benefit of patients,” said Michel Spagnol, chairman and CEO of Novasep. “Specifically, this expansion allows us to create more than 30 full-time jobs in Le Mans.”